CY1121173T1 - Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων - Google Patents
Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτωνInfo
- Publication number
- CY1121173T1 CY1121173T1 CY20191100095T CY191100095T CY1121173T1 CY 1121173 T1 CY1121173 T1 CY 1121173T1 CY 20191100095 T CY20191100095 T CY 20191100095T CY 191100095 T CY191100095 T CY 191100095T CY 1121173 T1 CY1121173 T1 CY 1121173T1
- Authority
- CY
- Cyprus
- Prior art keywords
- antibodies
- human
- nextion
- specificated
- tumors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000057041 human TNF Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Compression Of Band Width Or Redundancy In Fax (AREA)
Abstract
Περιγράφονται μόρια αντισωμάτων που περιέχουν τουλάχιστον ένα CDR προερχόμενο από μονοκλωνικά αντισώματα ποντικού, με ειδικότητα προς τον ανθρώπινο TNFα. Περιγράφεται επίσης ένα CDR μοσχευμένο αντίσωμα όπου τουλάχιστον ένα από τα CDR είναι ένα υβριδικό CDR. Περιγράφονται επιπλέον αλληλουχίες DNA που κωδικοποιούν τις αλυσίδες των αντισωμάτων, φορείς, μετασχηματισμένα κύτταρα ξενιστές και χρήσεις των αντισωμάτων για την θεραπεία νοσημάτων που διαμεσολαβούνται από τον TNFα.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0013810.7A GB0013810D0 (en) | 2000-06-06 | 2000-06-06 | Biological products |
EP10010795.2A EP2308975B1 (en) | 2000-06-06 | 2001-06-05 | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
EP09176251A EP2230308B1 (en) | 2000-06-06 | 2001-06-05 | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
PCT/GB2001/002477 WO2001094585A1 (en) | 2000-06-06 | 2001-06-05 | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
EP01934209A EP1287140B1 (en) | 2000-06-06 | 2001-06-05 | Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1121173T1 true CY1121173T1 (el) | 2020-05-29 |
Family
ID=9893121
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100219T CY1109889T1 (el) | 2000-06-06 | 2010-03-09 | Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων |
CY2010011C CY2010011I1 (el) | 2000-06-06 | 2010-05-13 | Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων |
CY20131100333T CY1114143T1 (el) | 2000-06-06 | 2013-04-23 | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων |
CY20161101159T CY1118220T1 (el) | 2000-06-06 | 2016-11-10 | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων |
CY20191100095T CY1121173T1 (el) | 2000-06-06 | 2019-01-24 | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων |
CY2019018C CY2019018I1 (el) | 2000-06-06 | 2019-04-19 | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100219T CY1109889T1 (el) | 2000-06-06 | 2010-03-09 | Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων |
CY2010011C CY2010011I1 (el) | 2000-06-06 | 2010-05-13 | Μορια αντισωματος που εμφανιζουν ειδικοτητα για ανθρωπινο παραγοντα νεκρωσης ογκων α, και χρηση αυτων |
CY20131100333T CY1114143T1 (el) | 2000-06-06 | 2013-04-23 | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων |
CY20161101159T CY1118220T1 (el) | 2000-06-06 | 2016-11-10 | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2019018C CY2019018I1 (el) | 2000-06-06 | 2019-04-19 | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων |
Country Status (43)
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
GB0129105D0 (en) * | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
US20060171940A1 (en) * | 2002-03-20 | 2006-08-03 | Celltech R&D Limited | Antibody disulfide isomers, use thereof, and methods of analyzing same |
US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
BR122019027966B8 (pt) | 2002-05-02 | 2021-07-27 | Wyeth Corp | conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
US7601817B2 (en) | 2002-05-28 | 2009-10-13 | Ucb Pharma S.A. | Antibody peg positional isomers, compositions comprising same, and use thereof |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EP2298810A3 (en) * | 2002-07-19 | 2011-08-03 | Abbott Biotechnology Ltd | Treatment of TNF alpha related disorders |
US20040247588A1 (en) * | 2002-08-28 | 2004-12-09 | Johnson Robert E. | Formulations of modified antibodies and methods of making the same |
AU2003265361A1 (en) * | 2002-08-28 | 2004-03-19 | Pharmacia Corporation | Stable ph optimized formulation of a modified antibody |
US20040105858A1 (en) * | 2002-08-29 | 2004-06-03 | Kim Joanne Young Hee Kwak | Diagnosis and treatment of infertility |
MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
CN101899106A (zh) | 2002-10-29 | 2010-12-01 | 阿纳福公司 | 三聚细胞因子的三聚结合蛋白 |
US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
WO2004065417A2 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
WO2004074345A2 (en) * | 2003-02-19 | 2004-09-02 | Pharmacia Corporation | Carbonate esters of polyethylene glycol activated by means of oxalate esters |
WO2004098578A2 (en) * | 2003-05-12 | 2004-11-18 | Altana Pharma Ag | Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517 |
CA2529819A1 (en) * | 2003-06-30 | 2004-09-23 | Domantis Limited | Pegylated single domain antibodies |
WO2005014649A2 (en) * | 2003-08-08 | 2005-02-17 | Pharmacia Corporation | Method for the preparation of molecules having antibody activity |
ES2281822T3 (es) * | 2003-08-13 | 2007-10-01 | Sandoz Ag | Vectores de expresion, celulas huesped transformadas y procedimiento de fermentacion para la produccion de polipeptidos recombinantes. |
SI1656455T1 (sl) * | 2003-08-13 | 2012-12-31 | Sandoz Ag | Postopek za čiščenje rekombinantnih polipeptidov |
GB0319601D0 (en) | 2003-08-20 | 2003-09-24 | Sandoz Ag | Production process |
KR100570422B1 (ko) * | 2003-10-16 | 2006-04-11 | 한미약품 주식회사 | 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법 |
CN100393748C (zh) * | 2003-11-06 | 2008-06-11 | 上海中信国健药业有限公司 | 全人源肿瘤坏死因子抗体,其制备方法以及药物组合物 |
KR100772800B1 (ko) * | 2003-11-17 | 2007-11-01 | 주식회사유한양행 | 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자 |
US7435799B2 (en) | 2004-01-08 | 2008-10-14 | Applied Molecular Evolution | TNF-α binding molecules |
CN100427504C (zh) * | 2004-06-02 | 2008-10-22 | 北京天广实生物技术有限公司 | TNFα高亲和力嵌合抗体及其用途 |
JP2008504356A (ja) * | 2004-06-30 | 2008-02-14 | ドマンティス リミテッド | 炎症性疾患を治療するための組成物及び方法 |
GB0425972D0 (en) * | 2004-11-25 | 2004-12-29 | Celltech R&D Ltd | Biological products |
WO2006062776A2 (en) * | 2004-11-29 | 2006-06-15 | The Regents Of The University Of California | Hydroxyapatite-binding peptides for bone growth and inhibition |
ATE499385T1 (de) * | 2004-12-29 | 2011-03-15 | Yuhan Corp | Tumornekrosefaktor-alpha spezifische humanisierte antikörper |
CA2903138A1 (en) | 2005-05-16 | 2006-11-23 | Abbvie Biotechnology Ltd. | Use of tnfa inhibitor for treatment of erosive polyarthritis |
NZ563213A (en) * | 2005-06-01 | 2009-07-31 | Micromet Ag | Anti-IL2 antibodies |
CN102924597A (zh) | 2005-06-07 | 2013-02-13 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 抑制TNFα的稳定和可溶的抗体 |
GB0520169D0 (en) * | 2005-10-04 | 2005-11-09 | Celltech R&D Ltd | Biological products |
EP2004231A4 (en) * | 2006-04-07 | 2013-07-10 | Nektar Therapeutics | CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2007426A4 (en) * | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS |
US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
JP5385135B2 (ja) | 2006-07-03 | 2014-01-08 | チャールズ デイビッド アデア, | 細胞接着分子の発現を調節するための組成物 |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
JP5452236B2 (ja) * | 2007-03-02 | 2014-03-26 | ファーナム・カンパニーズ・インコーポレーテッド | ロウ様物質を用いた徐放性組成物 |
EP2166844A4 (en) * | 2007-06-07 | 2013-09-04 | Evonik Corp | DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS |
WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
WO2009097704A1 (en) * | 2008-02-05 | 2009-08-13 | Esbatech Ag | Antigen-binding polypeptides against cartilage degeneration |
BRPI0912570B8 (pt) * | 2008-05-07 | 2021-05-25 | Argos Therapeutics Inc | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos |
KR102007492B1 (ko) | 2008-06-25 | 2019-08-05 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화 |
PL3216803T3 (pl) | 2008-06-25 | 2020-10-19 | Novartis Ag | Stabilne i rozpuszczalne przeciwciała hamujące vegf |
PL3628686T3 (pl) | 2008-06-25 | 2022-02-28 | Novartis Ag | Humanizowanie przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała |
HUE039692T2 (hu) | 2008-06-25 | 2019-01-28 | Esbatech Alcon Biomed Res Unit | TNF-et gátló stabil és oldható ellenanyagok |
CN101684156B (zh) * | 2008-09-27 | 2011-12-28 | 苏州工业园区晨健抗体组药物开发有限公司 | 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用 |
RU2011135768A (ru) * | 2009-01-29 | 2013-03-10 | Эбботт Лэборетриз | Белки, связывающие il-1 |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
HUE051430T2 (hu) | 2009-07-10 | 2021-03-01 | Ablynx Nv | Eljárás variábilis domének elõállítására |
IN2012DN02401A (el) | 2009-09-24 | 2015-08-21 | Ucb Pharma Sa | |
US8785600B2 (en) | 2009-10-23 | 2014-07-22 | Millennium Pharmaceuticals, Inc. | Anti-GCC antibody molecules and related compositions and methods |
GB201000590D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
GB201000591D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000587D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial hoist strain |
GB201000588D0 (en) | 2010-01-14 | 2010-03-03 | Ucb Pharma Sa | Bacterial host strain |
GB201001791D0 (en) | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
US9616120B2 (en) | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
JP2013520999A (ja) | 2010-03-04 | 2013-06-10 | ベット・セラピューティクス・インコーポレイテッド | Cd52に対するモノクローナル抗体 |
RU2012147249A (ru) | 2010-04-07 | 2014-05-20 | Эббви Инк. | TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ |
GB201012599D0 (en) * | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
GB201012603D0 (en) * | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
GB201012784D0 (en) * | 2010-07-29 | 2010-09-15 | Ucb Pharma Sa | Method |
TWI538918B (zh) | 2010-10-20 | 2016-06-21 | 財團法人工業技術研究院 | 人源化之單株抗體、其核苷酸序列與其用途 |
AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
WO2012164083A1 (en) | 2011-06-01 | 2012-12-06 | Actogenix N.V. | Polycistronic expression system for bacteria |
BR112013032871B1 (pt) | 2011-07-13 | 2022-09-27 | Ucb Pharma S.A. | Cepa hospedeira bacteriana que expressa dsbc recombinante e método para produzir anticorpo ou fragmento de ligação de antígeno deste que se liga especificamente a cd154 |
EP2546267A1 (en) | 2011-07-13 | 2013-01-16 | UCB Pharma S.A. | Bacterial host strain expressing recombinant DsbC |
US9347036B2 (en) | 2011-09-23 | 2016-05-24 | Intrexon Actobiotics Nv | Modified gram positive bacteria and uses thereof |
DK2758512T3 (en) | 2011-09-23 | 2018-07-23 | Intrexon Actobiotics Nv | MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF |
EP2791169B1 (en) | 2011-12-16 | 2017-07-19 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
GB201208367D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Biological product |
MX357675B (es) | 2012-08-13 | 2018-07-18 | Genentech Inc | Anticuerpos anti-jagged y métodos de uso. |
EP3134439B1 (en) | 2014-04-21 | 2018-12-26 | Millennium Pharmaceuticals, Inc. | Anti-psyk antibody molecules and use of same for syk-targeted therapy |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
EP3220961B1 (en) | 2014-10-22 | 2023-07-05 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
JP6807326B2 (ja) | 2014-12-22 | 2021-01-06 | ユーシービー バイオファルマ エスアールエル | タンパク質製造方法 |
WO2017035430A2 (en) * | 2015-08-27 | 2017-03-02 | Kolltan Pharmaceuticals, Inc. | Anti-alk antibodies and methods for use thereof |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
DK3402499T3 (da) | 2016-01-14 | 2021-09-27 | Intrexon Actobiotics Nv | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes |
RU2680011C2 (ru) * | 2016-04-29 | 2019-02-14 | Закрытое Акционерное Общество "Биокад" | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы |
AU2017274442B2 (en) | 2016-06-02 | 2021-08-19 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
EP3884962A1 (en) | 2017-12-01 | 2021-09-29 | AbbVie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
SG11202107995SA (en) | 2019-01-31 | 2021-08-30 | Numab Therapeutics AG | Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof |
KR102323342B1 (ko) * | 2019-04-26 | 2021-11-08 | 주식회사 와이바이오로직스 | IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체 |
CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
TW202237638A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
TW202237639A (zh) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | 鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法 |
IL305181A (en) | 2021-02-15 | 2023-10-01 | Takeda Pharmaceuticals Co | Cell therapy compositions and methods for modulating TGF-B signaling |
CN117500816A (zh) | 2021-08-26 | 2024-02-02 | 映恩生物制药(苏州)有限公司 | 一种甾体化合物及其缀合物 |
SE545714C2 (en) * | 2021-09-24 | 2023-12-19 | Xbrane Biopharma Ab | Dna contructs for producing a pelb signal peptide |
WO2023046930A1 (en) | 2021-09-24 | 2023-03-30 | Xbrane Biopharma Ab | Dna constructs and host cells for expressing recombinant protein |
SE545694C2 (en) * | 2021-09-24 | 2023-12-05 | Xbrane Biopharma Ab | Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides |
WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
US5030570A (en) | 1988-06-30 | 1991-07-09 | The Eunice Kennedy Shriver Center For Mental Retardation | DNA encoding and method of expressing human monoamine oxidase type A |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
PT92900A (pt) * | 1989-01-24 | 1990-07-31 | Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos | |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
NO309690B1 (no) | 1995-01-23 | 2001-03-12 | Western Atlas Int Inc | Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn |
CA2218522A1 (en) | 1995-04-20 | 1996-10-24 | The Kennedy Institute Of Rheumatology | Multiple administrations of anti-tnf antibody |
DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
CA2297692A1 (en) * | 1997-08-18 | 1999-02-25 | Innogenetics N.V. | Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders |
GB9720054D0 (en) * | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
PT1061954E (pt) | 1998-03-12 | 2004-10-29 | Nektar Therapeutics Al Corp | Derivados de poli(etileno glicol) com grupos reactivos proximos |
GB9812545D0 (en) * | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
-
2000
- 2000-06-06 GB GBGB0013810.7A patent/GB0013810D0/en not_active Ceased
-
2001
- 2001-06-05 PL PL399351A patent/PL218516B1/pl unknown
- 2001-06-05 HU HU0202346A patent/HU230561B1/hu active Protection Beyond IP Right Term
- 2001-06-05 SI SI200131020T patent/SI2230308T1/sl unknown
- 2001-06-05 TR TR2019/00227T patent/TR201900227T4/tr unknown
- 2001-06-05 IL IL14799201A patent/IL147992A0/xx unknown
- 2001-06-05 KR KR1020027001131A patent/KR20020047097A/ko active Search and Examination
- 2001-06-05 HU HU1600016A patent/HU230553B1/hu unknown
- 2001-06-05 DE DE10192353T patent/DE10192353T1/de not_active Withdrawn
- 2001-06-05 PL PL353960A patent/PL212738B1/pl unknown
- 2001-06-05 AP APAP/P/2002/002690A patent/AP2092A/en active
- 2001-06-05 AU AU60511/01A patent/AU783756B2/en active Active
- 2001-06-05 PT PT91762518T patent/PT2230308E/pt unknown
- 2001-06-05 DK DK09176251.8T patent/DK2230308T3/da active
- 2001-06-05 SI SI200130960T patent/SI1287140T1/sl unknown
- 2001-06-05 EP EP16154916.7A patent/EP3059314B1/en not_active Expired - Lifetime
- 2001-06-05 DK DK16154916.7T patent/DK3059314T3/en active
- 2001-06-05 MX MXPA01013440A patent/MXPA01013440A/es active IP Right Grant
- 2001-06-05 BR BR0106682-0A patent/BR0106682A/pt not_active IP Right Cessation
- 2001-06-05 ES ES10010795.2T patent/ES2600080T3/es not_active Expired - Lifetime
- 2001-06-05 MY MYPI20012634A patent/MY136603A/en unknown
- 2001-06-05 ES ES09176251T patent/ES2403217T3/es not_active Expired - Lifetime
- 2001-06-05 DK DK10010795.2T patent/DK2308975T3/da active
- 2001-06-05 SK SK315-2002A patent/SK288343B6/sk not_active IP Right Cessation
- 2001-06-05 SI SI200131056A patent/SI2308975T1/sl unknown
- 2001-06-05 LT LTEP10010795.2T patent/LT2308975T/lt unknown
- 2001-06-05 CA CA2380298A patent/CA2380298C/en not_active Expired - Lifetime
- 2001-06-05 GB GB0128386A patent/GB2366800B/en not_active Expired - Lifetime
- 2001-06-05 JP JP2002502126A patent/JP4064812B2/ja not_active Expired - Lifetime
- 2001-06-05 WO PCT/GB2001/002477 patent/WO2001094585A1/en active Application Filing
- 2001-06-05 RU RU2002105922/13A patent/RU2303604C2/ru active Protection Beyond IP Right Term
- 2001-06-05 ES ES01934209T patent/ES2337763T3/es not_active Expired - Lifetime
- 2001-06-05 BR BRPI0106682A patent/BRPI0106682B8/pt not_active IP Right Cessation
- 2001-06-05 DE DE122010000027C patent/DE122010000027I1/de active Pending
- 2001-06-05 PT PT01934209T patent/PT1287140E/pt unknown
- 2001-06-05 HU HUP1600483A patent/HU230669B1/hu unknown
- 2001-06-05 NZ NZ516596A patent/NZ516596A/en not_active IP Right Cessation
- 2001-06-05 PT PT16154916T patent/PT3059314T/pt unknown
- 2001-06-05 EP EP10010795.2A patent/EP2308975B1/en not_active Expired - Lifetime
- 2001-06-05 EP EP09176251A patent/EP2230308B1/en not_active Expired - Lifetime
- 2001-06-05 PT PT100107952T patent/PT2308975T/pt unknown
- 2001-06-05 CA CA2707766A patent/CA2707766C/en not_active Expired - Lifetime
- 2001-06-05 DK DK01934209.6T patent/DK1287140T3/da active
- 2001-06-05 CN CNB018016294A patent/CN1289671C/zh not_active Expired - Lifetime
- 2001-06-05 OA OA1200200368A patent/OA12282A/en unknown
- 2001-06-05 ES ES16154916T patent/ES2707714T3/es not_active Expired - Lifetime
- 2001-06-05 ES ES200250012A patent/ES2230975B2/es not_active Expired - Lifetime
- 2001-06-05 AT AT01934209T patent/ATE451460T1/de active
- 2001-06-05 EP EP01934209A patent/EP1287140B1/en not_active Expired - Lifetime
- 2001-06-05 CZ CZ20020837A patent/CZ300737B6/cs unknown
- 2001-06-05 DE DE60140738T patent/DE60140738D1/de not_active Expired - Lifetime
- 2001-06-06 TW TW090113707A patent/TWI316088B/zh active
- 2001-06-06 AR ARP010102689A patent/AR033978A1/es active IP Right Grant
- 2001-06-06 US US09/875,221 patent/US7012135B2/en not_active Expired - Lifetime
- 2001-06-06 PE PE2001000529A patent/PE20020292A1/es active IP Right Grant
- 2001-06-06 TW TW096150671A patent/TWI353358B/zh not_active IP Right Cessation
- 2001-09-10 US US09/949,559 patent/US7186820B2/en not_active Expired - Lifetime
-
2002
- 2002-01-03 IS IS6217A patent/IS2808B/is unknown
- 2002-01-04 BG BG106278A patent/BG66072B1/bg unknown
- 2002-01-04 ZA ZA200200097A patent/ZA200200097B/xx unknown
- 2002-02-04 IL IL147992A patent/IL147992A/en active IP Right Grant
- 2002-02-04 NO NO20020554A patent/NO334808B1/no not_active IP Right Cessation
- 2002-02-06 EC EC2002004210A patent/ECSP024210A/es unknown
-
2003
- 2003-05-22 HK HK03103635.2A patent/HK1051385A1/xx not_active IP Right Cessation
-
2006
- 2006-03-13 US US11/374,231 patent/US7402662B2/en not_active Expired - Lifetime
- 2006-10-19 JP JP2006285205A patent/JP4476989B2/ja not_active Expired - Lifetime
-
2008
- 2008-06-18 US US12/141,667 patent/US7977464B2/en not_active Expired - Fee Related
- 2008-11-03 IL IL195085A patent/IL195085A0/en unknown
-
2009
- 2009-01-09 JP JP2009003953A patent/JP5185143B2/ja not_active Expired - Lifetime
-
2010
- 2010-03-09 CY CY20101100219T patent/CY1109889T1/el unknown
- 2010-03-15 FR FR10C0015C patent/FR10C0015I2/fr active Active
- 2010-03-29 LU LU91674C patent/LU91674I2/fr unknown
- 2010-04-13 BE BE2010C019C patent/BE2010C019I2/fr unknown
- 2010-05-13 CY CY2010011C patent/CY2010011I1/el unknown
-
2011
- 2011-03-22 HK HK11102887.9A patent/HK1148776A1/xx not_active IP Right Cessation
- 2011-11-18 IS IS8986A patent/IS3016B/is unknown
-
2013
- 2013-04-23 CY CY20131100333T patent/CY1114143T1/el unknown
- 2013-10-01 NO NO20131316A patent/NO339282B1/no not_active IP Right Cessation
-
2014
- 2014-10-23 NO NO2014026C patent/NO2014026I2/no unknown
-
2016
- 2016-04-26 NO NO20160694A patent/NO341218B1/no not_active IP Right Cessation
- 2016-11-10 CY CY20161101159T patent/CY1118220T1/el unknown
-
2017
- 2017-04-06 HU HUS1700013C patent/HUS1700013I1/hu unknown
-
2019
- 2019-01-24 CY CY20191100095T patent/CY1121173T1/el unknown
- 2019-04-19 CY CY2019018C patent/CY2019018I1/el unknown
- 2019-04-24 NL NL300982C patent/NL300982I9/nl unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1121173T1 (el) | Μορια αντισωματων εξειδικευμενα για τον ανθρωπινο παραγοντα νεκρωσης των ογκων αλφα, και χρηση αυτων | |
CY1110134T1 (el) | Αντισωματα ειδικα για το cd22 και η θεραπευτικη και διαγνωστικη χρηση τους | |
DE60237778D1 (de) | Antikörper gegen kdr, deren herstellung und verwendungen | |
ATE454903T1 (de) | Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper | |
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
CY1116167T1 (el) | Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1 | |
ATE461938T1 (de) | Mit entzündlichen darmerkrankungen (ibd) assoziierte mikrobielle antigene und verfahren derer anwendung | |
CY1109645T1 (el) | Ανθρωπινος πρωτεϊνικος υποδοχεας τυπου toll, σχετικα αντιδραστηρια και μεθοδοι | |
DE69734109D1 (de) | Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung | |
WO2003050243A3 (en) | Novel genes encoding colon cancer antigens | |
ATE214734T1 (de) | Gegen das a33 antigen gerichtete humanisierte antikörper | |
ATE205532T1 (de) | Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper | |
DE60129278D1 (de) | Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen | |
UY26266A1 (es) | Antigeno asociado con tumores (r11) ley 17164 | |
DE602004029394D1 (de) | Antikörper variable region eines monoklonalen antikörpers gegen den humanen tumor nekrose faktor-alpha und dafür kodierendes gen | |
ATE288960T1 (de) | Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 | |
UY26170A1 (es) | Antigeno (c42) asociados a tumores | |
BR9815776A (pt) | Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade |